Case Study

Listen to how Dr. Loewe leveraged TissueCypher to upstage treatment for a highly anxious patient with a long history of GERD and recent trouble swallowing.  

“[The patient] said to me: ‘Are you going to do anything with my Barrett’s at this time’…I said, ‘TissueCypher will give us that answer to lower your anxiety.’ ”

Case details

  • No family history of EAC
  • BMI 25
  • 25 years of chronic GERD
  • Daily PPI:  Rabeprazole 40 mg
  • Non-smoker
  • Difficulty swallowing related to GERD
  • High anxiety level related to the potential development of EAC
  • Last EGD 3 years ago for surveillance of NDBE
Case Study

Listen to how Dr. Loewe leveraged TissueCypher to upstage treatment for a highly anxious patient with a long history of GERD and recent trouble swallowing.  

“[The patient] said to me: ‘Are you going to do anything with my Barrett’s at this time’…I said, ‘TissueCypher will give us that answer to lower your anxiety.’ ”

Case details

  • No family history of EAC
  • BMI 25
  • 25 years of chronic GERD
  • Daily PPI:  Rabeprazole 40 mg
  • Non-smoker
  • Difficulty swallowing related to GERD
  • High anxiety level related to the potential development of EAC
  • Last EGD 3 years ago for surveillance of NDBE
Case Study

Listen to how Dr. Loewe leveraged TissueCypher to upstage treatment for a highly anxious patient with a long history of GERD and recent trouble swallowing.  

“[The patient] said to me: ‘Are you going to do anything with my Barrett’s at this time’…I said, ‘TissueCypher will give us that answer to lower your anxiety.’ ”

Case details

  • No family history of EAC
  • BMI 25
  • 25 years of chronic GERD
  • Daily PPI:  Rabeprazole 40 mg
  • Non-smoker
  • Difficulty swallowing related to GERD
  • High anxiety level related to the potential development of EAC
  • Last EGD 3 years ago for surveillance of NDBE
Dr. Charles Loewe: Case 1

Clinical risk factors

A 74-year-old male patient with a long history of GERD presented to Dr. Loewe with difficulty swallowing. Previous surveillance endoscopies from 3 years prior showed non-dysplastic Barrett’s esophagus.

RELEVANT MEDICAL HISTORY
  • No family history of EAC
  • BMI 25
  • 25 years of chronic GERD
  • Daily PPI:  Rabeprazole 40 mg
  • Non-smoker
ADDITIONAL CONSIDERATIONS
  • Difficulty swallowing related to GERD
  • High anxiety level related to the potential development of EAC
  • Last EGD 3 years ago for surveillance of NDBE

Endoscopic findings

The endoscopy confirmed the presence of long-segment non-dysplastic Barrett’s esophagus by both traditional pathology and WATS3D.

Lower esophagus:
  • BE segment: C4M5
  • 2 cm hiatal hernia​
  • Non-dysplastic pathology
  • WATS3D-confirmed NDBE
Traditional Management:
  • Clinical profile: Low risk due to NDBE
  • Treatment recommendation: 3-5 yr surveillance

TissueCypher results

TissueCypher results showed an intermediate-risk classification with a 5-year risk of progression of 7%, approaching the progression risk of confirmed low-grade dysplasia. Through shared decision-making, Dr. Loewe and the patient opted to remove the precancerous tissue using Endoscopic Eradication Therapy (EET).  

  • Risk class: Intermediate
  • Risk score: 5.5
  • 5-year risk of progression: 7%

TissueCypher-guided management

  • Change in management: upstaged due to shared decision making

"Using shared decision making, [the patient] said to me 'I want you to get rid of that cancer risk'... and we proceeded with endoscopic eradication therapy."

Charles Loewe, MD